Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

The global lipid nanoparticles market is on track to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, driven ...

Dealmaking is up this year and doesn’t look like it will slow down in 2025. Merck is an example of a company that could easily buy a smaller one.

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Corp. with ...

Merck narrowly secured backing for molnupiravir by FDA advisors in a meeting last month ... as an at-home treatment for mild-to-moderate COVID-19 in high-risk patients aged 12 and over who ...

The app attracted a lot of attention during the pandemic as a potentially way to differentiate COVID-19 ... few months after Merck suffered a setback in its attempt to secure FDA approval for ...

Rakovina Therapeutics is leveraging AI to accelerate the discovery of drug candidates for the treatment of cancer.

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Merck & Co (MRK) is down more than -2% after the latest data from trials of Summit Therapeutics lung cancer drug ivonescimab showed “statistically significant improvement” in progression-free survival ...